Recruiting diverse participants to treat peripheral artery disease (PAD), a costly and dangerous medical condition with mortality rates three times that of breast cancer, is of significant importance. Discover how Abbott improves underserved communities’ access to clinical trials, better serving the patients most affected by vascular disease. PAD predominantly affects African Americans, who are twice as likely to have PAD as any other racial/ethnic group and four times as likely to require an amputation. Therefore, it is critical that both the doctors and patients who participate in this clinical trial reflect the underserved communities most in need of treatment.
Join this session to learn: